[{"data":1,"prerenderedAt":195},["ShallowReactive",2],{"drug-pneumococcal-vaccine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":35,"contraindications":79,"warnings":89,"renal":90,"monitoring":91,"interactions":92,"review":93,"examples":96,"atc":107,"iran":109,"links":141,"populations":156,"usApproval":190},"pneumococcal-vaccine",1,{"fa":7,"en":8},"واکسن پنوموکوک کونژوگه (PCV20)","Pneumococcal conjugate vaccine (PCV20)","anti-infectives",{"fa":11,"en":12},"واکسن کونژوگه","Conjugate vaccine",[14],{"name":15,"market":16},"Prevnar 20","US",[18,19,20,21],"prevnar","پرونار","واکسن پنوموکوک","PCV",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":30,"refs":31},"syr-05","injection","im","0.5 mL prefilled syringe",{"amount":5,"unit":29,"perVolumeMl":5},"mL",[16],[32],{"source":33,"section":34},"fda-prevnar20","3",[36,65],{"id":37,"disease":38,"label":39,"population":42,"type":49,"unit":29,"dose":50,"refs":52,"durationDays":55,"notes":56},"child","immunization",{"fa":40,"en":41},"شیرخوار — ۰٫۵ mL در ۲، ۴، ۶ و ۱۲ تا ۱۵ ماهگی","Infant — 0.5 mL at 2, 4, 6 and 12–15 months",{"minAge":43,"maxAge":46},{"value":44,"unit":45},6,"week",{"value":47,"unit":48},18,"year","fixed",{"perDose":51,"dosesPerDay":5},0.5,[53],{"source":33,"section":54},"2.3",{"min":5,"max":5},[57],{"text":58,"refs":61},{"fa":59,"en":60},"دوز اول از ۶ هفتگی. جبرانی (بدون واکسن قبلی): ۷ تا ۱۱ ماه ۳ دوز؛ ۱۲ تا ۲۳ ماه ۲ دوز با فاصله ۲ ماه؛ ۲۴ ماه تا ۱۷ سال یک دوز.","First dose from 6 weeks. Catch-up (no prior PCV): 7–11 months 3 doses; 12–23 months 2 doses 2 months apart; 24 months–17 y one dose.",[62,63],{"source":33,"section":54},{"source":33,"section":64},"2.4, Table 1",{"id":66,"disease":38,"label":67,"population":70,"type":49,"unit":29,"dose":72,"refs":73,"durationDays":78},"adult",{"fa":68,"en":69},"بزرگسال ۱۸ سال به بالا — یک دوز ۰٫۵ mL","Adults ≥18 y — one 0.5 mL dose",{"minAge":71},{"value":47,"unit":48},{"perDose":51,"dosesPerDay":5},[74,76],{"source":33,"section":75},"2.6",{"source":33,"section":77},"2.2",{"min":5,"max":5},[80],{"id":81,"severity":82,"text":83,"refs":86},"allergy","block",{"fa":84,"en":85},"واکنش آلرژیک شدید به اجزای واکسن یا توکسوئید دیفتری.","Severe allergic reaction to a component or to diphtheria toxoid.",[87],{"source":33,"section":88},"4",[],[],[],[],{"status":94,"reviewer":95,"date":95},"unverified",null,[97,102],{"regimen":37,"formulation":24,"input":98,"expect":101},{"ageMonths":99,"weightKg":100},2,5,{"perDose":51,"mlPerDose":51},{"regimen":66,"formulation":24,"input":103,"expect":106},{"ageYears":104,"weightKg":105},65,70,{"perDose":51,"mlPerDose":51},[108],"J07AL02",{"status":110,"forms":111,"refs":136},"registered",[112,116,120,124,128,132],{"code":113,"en":114,"fa":115},"18819","VACCINE-PENUMOCOCCAL POLYSACCHARIDE CONJ. 0.5 ML SYRING","سرنگ واکسن–پنوموکوککال پولیساکچاراید کونج . ۰٫۵ میلی‌لیتر",{"code":117,"en":118,"fa":119},"18152","VACCINE-PNEUMOCOCCAL MONOVALENT SYRINGE","سرنگ واکسن–پنوموکوکی تک‌ظرفیتی",{"code":121,"en":122,"fa":123},"52315","PNEUMOCOCCAL VACCINE 10-VALANT INJECTION PARENTERAL  0.5 mL","فرآورده تزریقی واکسن پنوموکوکی ۱۰–والانت ۰٫۵ میلی‌لیتر",{"code":125,"en":126,"fa":127},"52316","PNEUMOCOCCAL VACCINE 10-VALANT INJECTION PARENTERAL  2 mL","فرآورده تزریقی واکسن پنوموکوکی ۱۰–والانت ۲ میلی‌لیتر",{"code":129,"en":130,"fa":131},"52708","PNEUMOCOCCAL VACCINE 10-VALANT INJECTION PARENTERAL  2.5 mL","فرآورده تزریقی واکسن پنوموکوکی ۱۰–والانت ۲٫۵ میلی‌لیتر",{"code":133,"en":134,"fa":135},"52215","PNEUMOCOCCAL VACCINE 23-VALANT INJECTION PARENTERAL  0.5 mL","فرآورده تزریقی واکسن پنوموکوکی ۲۳–والانت ۰٫۵ میلی‌لیتر",[137],{"source":138,"section":139,"url":140},"darooyab-generic","G-3498\u002FPneumococcal-Vaccines","https:\u002F\u002Fwww.darooyab.ir\u002FG-3498\u002FPneumococcal-Vaccines",[142,146,150,153],{"kind":143,"url":144,"label":145},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=125731","BLA125731",{"kind":147,"url":148,"label":149},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=d4e2cf51-e6a8-4103-bb1d-6120c6474ff8","FDA Prevnar 20",{"kind":151,"url":152,"label":108},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J07AL02",{"kind":154,"url":140,"label":155},"darooyab","Pneumococcal-Vaccines",{"pregnancy":157,"lactation":166,"pediatric":174,"geriatric":182},{"level":158,"text":159,"quote":162,"refs":163},"caution",{"fa":160,"en":161},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary All pregnancies have a risk of birth defect, loss, or other adverse outcomes.",[164],{"source":33,"section":165},"8.1",{"level":158,"text":167,"quote":170,"refs":171},{"fa":168,"en":169},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Data are not available to assess the effects of Prevnar 20 on the breastfed infant or on milk production\u002Fexcretion.",[172],{"source":33,"section":173},"8.2",{"level":158,"text":175,"quote":178,"refs":179},{"fa":176,"en":177},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The effectiveness of Prevnar 20 for the prevention of otitis media caused by serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F has been established in individuals 6 weeks through 5 years of age [see Clinical Studies (14.1) ] .",[180],{"source":33,"section":181},"8.4",{"level":158,"text":183,"quote":186,"refs":187},{"fa":184,"en":185},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Of the total number of Prevnar 20 recipients 18 years of age and older evaluated for safety in the 3 main clinical trials (N=4263), 26.7% (n=1138) were 65 years of age and older and 1.7% (n=72) were 80 years of age and older [see Clinical Studies (14.2) ] .",[188],{"source":33,"section":189},"8.5",{"kind":191,"refs":192,"id":145},"BLA",[193],{"source":33,"section":194},"SPL approval \u002F marketing category",1792108434368]